Cover Image
市場調查報告書

登革熱:開發中產品分析

Dengue Fever - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 363105
出版日期 內容資訊 英文 170 Pages
訂單完成後即時交付
價格
Back to Top
登革熱:開發中產品分析 Dengue Fever - Pipeline Review, H1 2017
出版日期: 2017年06月27日 內容資訊: 英文 170 Pages
簡介

本報告提供登革熱治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

登革熱概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

登革熱:企業開發中的治療藥

登革熱:大學/機關研究中的治療藥

登革熱:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

登革熱:企業開發中的產品

登革熱:大學/機關研究中的產品

登革熱治療藥的開發企業

  • Abivax S.A.
  • Agilvax, Inc.
  • Altravax, Inc.
  • Arbovax, Inc.
  • BCI Pharma
  • Bioneer Corporation
  • Biotron Limited
  • CalAsia Pharmaceuticals, Inc.
  • Cocrystal Pharma, Inc.
  • Codagenix, Inc.
  • Emergent BioSolutions Inc.
  • Ennaid Therapeutics, LLC
  • GlaxoSmithKline Plc
  • Globavir Biosciences, Inc.
  • Hawaii Biotech, Inc.
  • Humabs BioMed SA
  • Immunotope, Inc.
  • Immunovaccine, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Kineta, Inc.
  • Merck & Co., Inc.
  • Molplex Ltd.
  • NanoViricides, Inc.
  • Novartis AG
  • NovaTarg Therapeutics, Inc
  • Panacea Biotec Limited
  • ProtInhi B.V.
  • Sanofi Pasteur SA
  • Sarepta Therapeutics, Inc.
  • SIGA Technologies, Inc.
  • 武田藥品工業
  • TechnoVax, Inc.
  • Themis Bioscience GmbH
  • VaxInnate Corporation
  • Visterra, Inc.

登革熱:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

登革熱:暫停中的計劃

登革熱:中止開發的產品

登革熱:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9450IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever - Pipeline Review, H1 2017, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape.

Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dengue Fever - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dengue Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 25, 22 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 5, 10 and 12 molecules, respectively.

Dengue Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dengue Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Dengue Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dengue Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dengue Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dengue Fever (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dengue Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dengue Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Dengue Fever - Overview
  • Dengue Fever - Therapeutics Development
  • Dengue Fever - Therapeutics Assessment
  • Dengue Fever - Companies Involved in Therapeutics Development
  • Dengue Fever - Drug Profiles
  • Dengue Fever - Dormant Projects
  • Dengue Fever - Discontinued Products
  • Dengue Fever - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Dengue Fever, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Dengue Fever - Pipeline by Abivax SA, H1 2017
  • Dengue Fever - Pipeline by Altravax Inc, H1 2017
  • Dengue Fever - Pipeline by Biological Mimetics Inc, H1 2017
  • Dengue Fever - Pipeline by Bioneer Corp, H1 2017
  • Dengue Fever - Pipeline by Biotron Ltd, H1 2017
  • Dengue Fever - Pipeline by Emergent BioSolutions Inc, H1 2017
  • Dengue Fever - Pipeline by Ennaid Therapeutics LLC, H1 2017
  • Dengue Fever - Pipeline by GeneSegues Inc, H1 2017
  • Dengue Fever - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Dengue Fever - Pipeline by Globavir Biosciences Inc, H1 2017
  • Dengue Fever - Pipeline by Griffith University, H1 2017
  • Dengue Fever - Pipeline by Hawaii Biotech Inc, H1 2017
  • Dengue Fever - Pipeline by Humabs BioMed SA, H1 2017
  • Dengue Fever - Pipeline by Immunotope Inc, H1 2017
  • Dengue Fever - Pipeline by Indian Immunologicals Ltd, H1 2017
  • Dengue Fever - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Dengue Fever - Pipeline by Johnson & Johnson, H1 2017
  • Dengue Fever - Pipeline by Kineta Inc, H1 2017
  • Dengue Fever - Pipeline by Merck & Co Inc, H1 2017
  • Dengue Fever - Pipeline by Molplex Ltd, H1 2017
  • Dengue Fever - Pipeline by NanoViricides Inc, H1 2017
  • Dengue Fever - Pipeline by Novartis AG, H1 2017
  • Dengue Fever - Pipeline by NovaTarg Therapeutics Inc, H1 2017
  • Dengue Fever - Pipeline by Panacea Biotec Ltd, H1 2017
  • Dengue Fever - Pipeline by Plex Pharmaceuticals Inc, H1 2017
  • Dengue Fever - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Dengue Fever - Pipeline by Sarepta Therapeutics Inc, H1 2017
  • Dengue Fever - Pipeline by SIGA Technologies Inc, H1 2017
  • Dengue Fever - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Dengue Fever - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Dengue Fever - Pipeline by TechnoVax Inc, H1 2017
  • Dengue Fever - Pipeline by Themis Bioscience GmbH, H1 2017
  • Dengue Fever - Pipeline by Visterra Inc, H1 2017
  • Dengue Fever - Pipeline by VLP Therapeutics LLC, H1 2017
  • Dengue Fever - Dormant Projects, H1 2017
  • Dengue Fever - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Dengue Fever - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Dengue Fever - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Dengue Fever - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Dengue Fever, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top